Download Advances in Immunology by Frank J. Dixon (Eds.) PDF

  • admin
  • April 20, 2017
  • Hematology
  • Comments Off on Download Advances in Immunology by Frank J. Dixon (Eds.) PDF

By Frank J. Dixon (Eds.)

This quantity includes the cumulative topic index for volumes 37 to sixty five of the "Advances in Immunology" sequence.

Show description

Read or Download Advances in Immunology PDF

Similar hematology books

Biotechnology of plasma proteins

''Discussing the function of plasma proteins in present biotechnology, this publication describes the protein composition of human plasma, the fractionation of plasma to procure healing proteins, and the research of those items. It delineates the trail from plasma items to recombinant items, and highlights items from albumin, intravenous immunoglobins, and coagulation.

Facharzt Hämatologie Onkologie

Das gesamte Facharztwissen klar strukturiert – zum schnellen Nachschlagen im klinischen Alltag und zur gezielten Vorbereitung auf die Facharztprüfung. Umfassende Darstellung von Epidemiologie, Histologie, Klassifikation, Diagnostik und Differenzialdiagnose der einzelnen Erkrankungen Detaillierte Angaben zur Therapie mit Behandlungsalgorithmen und differenzierten TherapieschemataIntegration der neuesten WHO-Klassifikation sowie aktueller LeitlinienAusführliche Informationen zu allen zugelassenen antineoplastischen Substanzen mit besonderer Berücksichtigung der modernen zielgerichteten TherapeutikaInklusive Schmerztherapie, Substitutionstherapie und anderen supportiven BehandlungsmaßnahmenNeu in der 2.

Hematology - Oncology Therapy

The basic remedy consultant to melanoma, Hematologic problems, and Supportive Care--Updated with the newest remedy Regimens greater than 500 remedy regimens Hematology-Oncology remedy, moment variation is an updated, finished remedy consultant that offers greater than 500 remedy regimens in a succinct, uniform demeanour.

Treatment of acute leukemias : new directions for clinical research

Pui (U. of Tennessee well-being technological know-how middle) provides forty two papers which are dedicated to deciding on and discussing pivotal matters that may be resolved via larger purposes of present equipment of leukemia administration, instead of expecting laboratory discoveries to force switch. Chapters examine

Additional info for Advances in Immunology

Example text

Ir genes and, 38:62, 63 Alloreactivity autoreactive T cells and, 45:420, 421, 425 B cell formation a d , 41:190 cytotoxic T cells and, 41:135-137. 169. -iiiicroglobiilin,41:156 amino acid, 41:159, 162, 163, 165 mrbohydrate nioirties. 41: lS3 exon shufHing 141, 41:142, 144-148 non no clonal antibodies, 41: 156- 158 soiriiitic cell class I variants, 41:167 hybrid resistance and, 41:357, 372, 380. 381 lininoral immune response and, 45:40 Zr genes and, 38:121-123 syiitlietic T arid B cell sites and, 45:234 T cell receptor and, 45:148-157 homogeneity, 45:128, 130 7 M HC molecules.

Tumor-specific, characteristics, 57:285 tumor, see Tumor antigens tumor immunogenicity affected by low level of expression, 57:303-305 uptake by B cells, 39:59-62 coinparison with macrophages, 39:60-62 Ig role, 39:60-62 valency, 59:302-305, 308 virus-induced immunosiippression and HIV, 45:351-353, 355-358,360-362, 365-367 measles, 45:339, 344, 346, 347 Antigen specificity Zr genes and alloreactivity, 38:121-123 antigen binding, 38:101, 106, 107 antigen processing, 38:96 B cell response, 38:50 cytotoxic T cells, 38:162, 164, 167, 171-174 expression, 3853, 55, 57, 60 gene function, 38:37, 38, 93 genetic regulation, 38:36, 37, 188 immunodominance, 38:181, 183, 184 macrophages, 38:111 MHC, 38:46 “Schlepper” experiment, 38:39, 40 T cells, 38:41-43 interactions, 38:153-158, 160 receptor, 38:115-117 selection, 38:131 suppression, 38:135, 136, 140, 149, 151, 152 lymphocytes hybridomas and B cells 286, 38:306 human-human hybridomaq, 38:296 Antigen-specific recognition, T cell cultures for, 42:165-166 Anti-€1-2Kk transgenic model, 52:311-313 Antiidiotypes, see Antibodies, anti-Id Antiidiotypic immunoregulation, B cell repertoire expression and, 42:35, 82 Antiidiotypic recognition, B cell repertoire expression and, 42:51-62 Antiinflammatory cytokines IL-6 effect, 54:27-28 during placentaVfetal development, 54:32 role in embryonic development, 5431-32 rheumatoid arthritis and, 64:291, 295-296 Antiinflammatory drugs mode of action, 64:172, 195-106 receptors, 52:402-404 receptors for, 52:402-404 Antiinflammatory and immunosuppressive molecules, NF-KB as target, 65:128-132 antioxidants and, 65:122- 123 anti-TNF-a antibodies, 65:123-124 CAMP and, 65:124-125 cyclosporin A and FK506, 65:120 deoxyspergualin and, 65:125-126 gliotoxin and, 65:126-127 glucocorticoids and, 65:118-120 gold compounds and, $5:123-124 rapamycin and, 65121 reactive oxygen intermediate-generating molecules and, 65:122-123 rheumatoid arthritis drugs and, 65:123-124 salicylates and, 65:121-122 sperguah, 65: 125- 126 steroids and, 65:118-120 Antimicrobial activity, NK cells and, 47:282-291 Antimitochondrial antibody, 49:219-220, 233, 249-250 Antinuclear antibodies, 44:93, 94; 49:210, 212, 219 autoantibodies biology, 44:136-138 rare occurrence, 44:125- 127 SUBJECT INDEX autoantigen function, 44:127.

See also Antigen recognition affinities to small molecules, 43:82 analysis of structure, 43:22 buried surface, 43232 chemistry and binding energy, 43:72-84 concerted shifts, 43:22 contact residue, 43:26 criteria for systematic studies, 43:5-8 critical residues, 43:27 crystallographic approaches, 43:4 degree of fidelity, 43:60 dominant epitopes and collective response, 43:46-49 electrostatic attraction, 43:80 evaluation of predictive methods criteria for assessing prediction success, 43:50-59 sequence data, 43:49-50 immunological cross-reactivity,43:64 interface adaptor hypothesis, 43: 125- 128 local antibody conformation effect, 43:17- 18 lock-and-keyfit, 43:78, 128 MHr, 43:42 mobile structural elements, 43:80 nature of immune response, 43:83 recognition and bindmg components, 43:79 reconciling crystallographic and peptide mapping data, 43:23-27 surface mobility role, 43:16-17 synthesis of structural description, 43:26 three-dimensional structures, 43:119-120 complementarity, 43:122 conformational changes, 43:123-125 15 epitope and paratope size, 43:120-121 epitope character, 43:121-122 X-ray crystallography,43:8-11 X-ray structures, 43:73 Antibody class switching, 61:79-81 heavy chain isotype expression, 61:82-84 problems in other studies, 61:81-82 regulation of isotype specificity, 61:84-89 switch recombination, 61:99-130 Antibody complexes, crystallographic structures, 43:4 Antibody-dependent cellular cytotoxicity, 41:269, 273; 46:114, 122; 58:223 adoptive T cell therapy of tumors and, 49:312-313 cytolysis and, 41:275.

Download PDF sample

Rated 4.41 of 5 – based on 12 votes